STX209
STX209 (arbaclofen), a selective GABA-B agonist, is hypothesized to modulate the balance of excitatory to inhibitory neurotransmission, and has shown preliminary evidence of benefit in fragile X syndrome. We evaluated its safety, tolerability, and efficacy in non-syndromic autism spectrum disorders,...
Gespeichert in:
| Veröffentlicht in: | Journal of autism and developmental disorders 2014-04, Vol.44 (4), p.958 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 4 |
| container_start_page | 958 |
| container_title | Journal of autism and developmental disorders |
| container_volume | 44 |
| creator | Erickson, Craig A Veenstra-Vanderweele, Jeremy M Melmed, Raun D McCracken, James T Ginsberg, Lawrence D Sikich, Linmarie Scahill, Lawrence Cherubini, Maryann Zarevics, Peter Walton-Bowen, Karen Carpenter, Randall L Bear, Mark F Wang, Paul P King, Bryan H |
| description | STX209 (arbaclofen), a selective GABA-B agonist, is hypothesized to modulate the balance of excitatory to inhibitory neurotransmission, and has shown preliminary evidence of benefit in fragile X syndrome. We evaluated its safety, tolerability, and efficacy in non-syndromic autism spectrum disorders, in an 8-week open-label trial enrolling 32 children and adolescents with either Autistic Disorder or Pervasive Developmental Disorder--Not Otherwise Specified, and a score [greater than or equal to]17 on the Aberrant Behavior Checklist (ABC)--Irritability subscale. STX209 was generally well-tolerated. The most common adverse events were agitation and irritability, which typically resolved without dose changes, and were often felt to represent spontaneous variation in underlying symptoms. Improvements were observed on several outcome measures in this exploratory trial, including the ABC-Irritability (the primary endpoint) and the Lethargy/Social Withdrawal subscales, the Social Responsiveness Scale, the CY-BOCSPDD, and clinical global impression scales. Placebo-controlled study of STX209 is warranted. |
| doi_str_mv | 10.1007/s10803-013-1963-z |
| format | Article |
| fullrecord | <record><control><sourceid>gale</sourceid><recordid>TN_cdi_gale_incontextgauss_ISR_A373257361</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A373257361</galeid><sourcerecordid>A373257361</sourcerecordid><originalsourceid>FETCH-gale_incontextgauss_ISR_A3732573613</originalsourceid><addsrcrecordid>eNpjYJA0NNAzNDAw1y82NLAwMNY1MDTWNbQ0M9atYmLgNDQ1N9Y1NjE2YmHgNDA0M9I1NjI152DgKi7OMjAwsLQwMuJkYAsOiTAysORhYE1LzClO5YXS3Ayabq4hzh666Yk5qfGZecn5eSWpFSXpiaXFxfGewUHxjsbmINOMzQyNSVELAM20LTY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>STX209</title><source>SpringerNature Journals</source><source>EBSCOhost Education Source</source><creator>Erickson, Craig A ; Veenstra-Vanderweele, Jeremy M ; Melmed, Raun D ; McCracken, James T ; Ginsberg, Lawrence D ; Sikich, Linmarie ; Scahill, Lawrence ; Cherubini, Maryann ; Zarevics, Peter ; Walton-Bowen, Karen ; Carpenter, Randall L ; Bear, Mark F ; Wang, Paul P ; King, Bryan H</creator><creatorcontrib>Erickson, Craig A ; Veenstra-Vanderweele, Jeremy M ; Melmed, Raun D ; McCracken, James T ; Ginsberg, Lawrence D ; Sikich, Linmarie ; Scahill, Lawrence ; Cherubini, Maryann ; Zarevics, Peter ; Walton-Bowen, Karen ; Carpenter, Randall L ; Bear, Mark F ; Wang, Paul P ; King, Bryan H</creatorcontrib><description>STX209 (arbaclofen), a selective GABA-B agonist, is hypothesized to modulate the balance of excitatory to inhibitory neurotransmission, and has shown preliminary evidence of benefit in fragile X syndrome. We evaluated its safety, tolerability, and efficacy in non-syndromic autism spectrum disorders, in an 8-week open-label trial enrolling 32 children and adolescents with either Autistic Disorder or Pervasive Developmental Disorder--Not Otherwise Specified, and a score [greater than or equal to]17 on the Aberrant Behavior Checklist (ABC)--Irritability subscale. STX209 was generally well-tolerated. The most common adverse events were agitation and irritability, which typically resolved without dose changes, and were often felt to represent spontaneous variation in underlying symptoms. Improvements were observed on several outcome measures in this exploratory trial, including the ABC-Irritability (the primary endpoint) and the Lethargy/Social Withdrawal subscales, the Social Responsiveness Scale, the CY-BOCSPDD, and clinical global impression scales. Placebo-controlled study of STX209 is warranted.</description><identifier>ISSN: 0162-3257</identifier><identifier>EISSN: 1573-3432</identifier><identifier>DOI: 10.1007/s10803-013-1963-z</identifier><language>eng</language><publisher>Springer</publisher><subject>Antipsychotic drugs ; Complications and side effects ; Dosage and administration ; Drug therapy ; Patient outcomes ; Pervasive developmental disorders ; Risk factors</subject><ispartof>Journal of autism and developmental disorders, 2014-04, Vol.44 (4), p.958</ispartof><rights>COPYRIGHT 2014 Springer</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Erickson, Craig A</creatorcontrib><creatorcontrib>Veenstra-Vanderweele, Jeremy M</creatorcontrib><creatorcontrib>Melmed, Raun D</creatorcontrib><creatorcontrib>McCracken, James T</creatorcontrib><creatorcontrib>Ginsberg, Lawrence D</creatorcontrib><creatorcontrib>Sikich, Linmarie</creatorcontrib><creatorcontrib>Scahill, Lawrence</creatorcontrib><creatorcontrib>Cherubini, Maryann</creatorcontrib><creatorcontrib>Zarevics, Peter</creatorcontrib><creatorcontrib>Walton-Bowen, Karen</creatorcontrib><creatorcontrib>Carpenter, Randall L</creatorcontrib><creatorcontrib>Bear, Mark F</creatorcontrib><creatorcontrib>Wang, Paul P</creatorcontrib><creatorcontrib>King, Bryan H</creatorcontrib><title>STX209</title><title>Journal of autism and developmental disorders</title><description>STX209 (arbaclofen), a selective GABA-B agonist, is hypothesized to modulate the balance of excitatory to inhibitory neurotransmission, and has shown preliminary evidence of benefit in fragile X syndrome. We evaluated its safety, tolerability, and efficacy in non-syndromic autism spectrum disorders, in an 8-week open-label trial enrolling 32 children and adolescents with either Autistic Disorder or Pervasive Developmental Disorder--Not Otherwise Specified, and a score [greater than or equal to]17 on the Aberrant Behavior Checklist (ABC)--Irritability subscale. STX209 was generally well-tolerated. The most common adverse events were agitation and irritability, which typically resolved without dose changes, and were often felt to represent spontaneous variation in underlying symptoms. Improvements were observed on several outcome measures in this exploratory trial, including the ABC-Irritability (the primary endpoint) and the Lethargy/Social Withdrawal subscales, the Social Responsiveness Scale, the CY-BOCSPDD, and clinical global impression scales. Placebo-controlled study of STX209 is warranted.</description><subject>Antipsychotic drugs</subject><subject>Complications and side effects</subject><subject>Dosage and administration</subject><subject>Drug therapy</subject><subject>Patient outcomes</subject><subject>Pervasive developmental disorders</subject><subject>Risk factors</subject><issn>0162-3257</issn><issn>1573-3432</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNpjYJA0NNAzNDAw1y82NLAwMNY1MDTWNbQ0M9atYmLgNDQ1N9Y1NjE2YmHgNDA0M9I1NjI152DgKi7OMjAwsLQwMuJkYAsOiTAysORhYE1LzClO5YXS3Ayabq4hzh666Yk5qfGZecn5eSWpFSXpiaXFxfGewUHxjsbmINOMzQyNSVELAM20LTY</recordid><startdate>20140401</startdate><enddate>20140401</enddate><creator>Erickson, Craig A</creator><creator>Veenstra-Vanderweele, Jeremy M</creator><creator>Melmed, Raun D</creator><creator>McCracken, James T</creator><creator>Ginsberg, Lawrence D</creator><creator>Sikich, Linmarie</creator><creator>Scahill, Lawrence</creator><creator>Cherubini, Maryann</creator><creator>Zarevics, Peter</creator><creator>Walton-Bowen, Karen</creator><creator>Carpenter, Randall L</creator><creator>Bear, Mark F</creator><creator>Wang, Paul P</creator><creator>King, Bryan H</creator><general>Springer</general><scope>ISR</scope></search><sort><creationdate>20140401</creationdate><title>STX209</title><author>Erickson, Craig A ; Veenstra-Vanderweele, Jeremy M ; Melmed, Raun D ; McCracken, James T ; Ginsberg, Lawrence D ; Sikich, Linmarie ; Scahill, Lawrence ; Cherubini, Maryann ; Zarevics, Peter ; Walton-Bowen, Karen ; Carpenter, Randall L ; Bear, Mark F ; Wang, Paul P ; King, Bryan H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-gale_incontextgauss_ISR_A3732573613</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Antipsychotic drugs</topic><topic>Complications and side effects</topic><topic>Dosage and administration</topic><topic>Drug therapy</topic><topic>Patient outcomes</topic><topic>Pervasive developmental disorders</topic><topic>Risk factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Erickson, Craig A</creatorcontrib><creatorcontrib>Veenstra-Vanderweele, Jeremy M</creatorcontrib><creatorcontrib>Melmed, Raun D</creatorcontrib><creatorcontrib>McCracken, James T</creatorcontrib><creatorcontrib>Ginsberg, Lawrence D</creatorcontrib><creatorcontrib>Sikich, Linmarie</creatorcontrib><creatorcontrib>Scahill, Lawrence</creatorcontrib><creatorcontrib>Cherubini, Maryann</creatorcontrib><creatorcontrib>Zarevics, Peter</creatorcontrib><creatorcontrib>Walton-Bowen, Karen</creatorcontrib><creatorcontrib>Carpenter, Randall L</creatorcontrib><creatorcontrib>Bear, Mark F</creatorcontrib><creatorcontrib>Wang, Paul P</creatorcontrib><creatorcontrib>King, Bryan H</creatorcontrib><collection>Gale In Context: Science</collection><jtitle>Journal of autism and developmental disorders</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Erickson, Craig A</au><au>Veenstra-Vanderweele, Jeremy M</au><au>Melmed, Raun D</au><au>McCracken, James T</au><au>Ginsberg, Lawrence D</au><au>Sikich, Linmarie</au><au>Scahill, Lawrence</au><au>Cherubini, Maryann</au><au>Zarevics, Peter</au><au>Walton-Bowen, Karen</au><au>Carpenter, Randall L</au><au>Bear, Mark F</au><au>Wang, Paul P</au><au>King, Bryan H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>STX209</atitle><jtitle>Journal of autism and developmental disorders</jtitle><date>2014-04-01</date><risdate>2014</risdate><volume>44</volume><issue>4</issue><spage>958</spage><pages>958-</pages><issn>0162-3257</issn><eissn>1573-3432</eissn><abstract>STX209 (arbaclofen), a selective GABA-B agonist, is hypothesized to modulate the balance of excitatory to inhibitory neurotransmission, and has shown preliminary evidence of benefit in fragile X syndrome. We evaluated its safety, tolerability, and efficacy in non-syndromic autism spectrum disorders, in an 8-week open-label trial enrolling 32 children and adolescents with either Autistic Disorder or Pervasive Developmental Disorder--Not Otherwise Specified, and a score [greater than or equal to]17 on the Aberrant Behavior Checklist (ABC)--Irritability subscale. STX209 was generally well-tolerated. The most common adverse events were agitation and irritability, which typically resolved without dose changes, and were often felt to represent spontaneous variation in underlying symptoms. Improvements were observed on several outcome measures in this exploratory trial, including the ABC-Irritability (the primary endpoint) and the Lethargy/Social Withdrawal subscales, the Social Responsiveness Scale, the CY-BOCSPDD, and clinical global impression scales. Placebo-controlled study of STX209 is warranted.</abstract><pub>Springer</pub><doi>10.1007/s10803-013-1963-z</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0162-3257 |
| ispartof | Journal of autism and developmental disorders, 2014-04, Vol.44 (4), p.958 |
| issn | 0162-3257 1573-3432 |
| language | eng |
| recordid | cdi_gale_incontextgauss_ISR_A373257361 |
| source | SpringerNature Journals; EBSCOhost Education Source |
| subjects | Antipsychotic drugs Complications and side effects Dosage and administration Drug therapy Patient outcomes Pervasive developmental disorders Risk factors |
| title | STX209 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T03%3A06%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=STX209&rft.jtitle=Journal%20of%20autism%20and%20developmental%20disorders&rft.au=Erickson,%20Craig%20A&rft.date=2014-04-01&rft.volume=44&rft.issue=4&rft.spage=958&rft.pages=958-&rft.issn=0162-3257&rft.eissn=1573-3432&rft_id=info:doi/10.1007/s10803-013-1963-z&rft_dat=%3Cgale%3EA373257361%3C/gale%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_galeid=A373257361&rfr_iscdi=true |